True North to acquire 2.4% stake in Biocon Biologics at a valuation of $3 billion | Mint
Cash-and-stock deal: Biocon Biologics acquires Viatris for $3.33 billion | The Financial Express
Biocon subsidiary acquires Viatris pharma for $3 billion | Mint
Biocon Campus - Biocon
Biocon Campus - Biocon
Biocon biosimilar plant criticized again by the FDA | Fierce Pharma
Biocon Campus - Biocon
Biocon Biologics enters licensing agreement with Yoshindo of Japan - The Hindu BusinessLine
Meet Biocon Biologics: A 2021 Facility of the Year Honorable Mention Award Winner | Pharmaceutical Engineering
Biocon logo in transparent PNG format
India's Biocon Biologics to receive $150m from Goldman Sachs - Nikkei Asia
Biocon Biologics Limited | ISPE | International Society for Pharmaceutical Engineering
Biocon Biologics to Acquire Viatris' Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
Research Centre - Biocon
Syngene International: Biocon sells 5.4% stake in arm Syngene International - The Economic Times
Biocon - 72 new faces joined us in February. Many... | Facebook
Research Centre - Biocon
Manufacturing Locations - Biocon
Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs - Biocon
Manufacturing Operations - Biocon - Global Biopharmaceutical company
Exclusive | Biocon, Mylan Biosimilar Deal in Last Leg; Serum Institute to Buy Additional Stake of $500 Million in Biocon Biologics: Sources
Covid has created an 'ecosystem' of innovation in India, says Biocon chief Kiran Mazumdar-Shaw | Mint
Biocon in pact with Japan's Yoshindo to commercialise two biosimilar assets | Mint
Biocon Q4 results show Consolidated revenue up by 21% - The Statesman
Biocon Biologics appoints Susheel Umesh as Chief Commercial Officer for emerging markets | Deccan Herald
Biocon announces merger of its arm with Serum Institute subsidiary - BusinessToday
